PSTV Earnings — PLUS THERAPEUTICS, Inc. Common Stock Post-ER Performance | BigEarnings
PSTV — PLUS THERAPEUTICS, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$5.82
Market Cap$40.1M
P/E—
52W Range$2.90 – $23.43
Next Earnings2026-08-13
About PLUS THERAPEUTICS, Inc. Common Stock
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
